Skip to main content
Premium Trial:

Request an Annual Quote

454 Life Sciences Receives $2.4M NIH Grant to Reduce Size, Cost of Sequencing Technology

NEW YORK, May 19 (GenomeWeb News) - 454 Life Sciences has received a $2.4 million NIH grant to miniaturize and lower the cost of its DNA sequencing technology, the company said today.

 

The two-year grant, from the National Human Genome Research Institute, is entitled "Massively Parallel High Throughput, Low Cost Sequencing." 454 Life Sciences, a majority-owned subsidiary of CuraGen, plans to use the funding to further reduce the size of the wells on its PicoTiter plate, to reduce the cost of sequencing per base, and to apply its technology to sequencing a whole fungal genome and large sections of a human genome.

 

According to the Branford, Conn.-based company, the technology enables researchers to sequence a genome with only one sample preparation.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.